MANATT, PHELPS, AND PHILLIPS

Lobbying for DENALI THERAPEUTICS · Biopharmaceutical Company

Filing 4th Quarter - Report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 13, 2026

Income

$70,000.00

What the client paid this registrant for the period.

Client based in

California

Lobbying activity 1

Health Issues

Rare Pediatric Disease Priority Review Voucher (PRV) Program Reauthorization; Rare disease drug development

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.